Status:

RECRUITING

Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations

Lead Sponsor:

Boston Children's Hospital

Collaborating Sponsors:

National Institutes of Health (NIH)

National Institute of Neurological Disorders and Stroke (NINDS)

Conditions:

PTEN

ASD

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural sy...

Detailed Description

Autism spectrum disorders (ASD) are a set of neurodevelopmental disorders characterized by social communication/interaction impairments and restricted/repetitive behaviors. ASD associated with germlin...

Eligibility Criteria

Inclusion Criteria

  • Individuals above the age of 18 months old at the time of consent who have documentation of a clinical diagnosis of autism spectrum disorder and/or a verified PTEN mutation from a medical or mental health professional for inclusion in the PTEN ASD, PTEN no-ASD or ASD macrocephaly groups.
  • Macrocephaly (head circumference greater than or equal to 98th percentile) for inclusion in the ASD macrocephaly group.
  • For youths, consent from parents or legal guardian. For adults, consent from self or legal guardian.
  • Youths who are able (some young or severely impaired participants may not be able to provide assent) will be asked to provide assent as per IRB guidelines.
  • Families with multiple children who meet the above inclusion criteria will be permitted to have as many children participate as they wish. A separate consent form will be filled out for each child enrolled in the study.
  • Primary communicative language must be English

Exclusion Criteria

  • Unwilling or unable to comply with study procedures and assessments
  • Clinically significant medical disease that would prohibit participation in the study procedures.
  • For subjects ELIGIBLE FOR OPTIONAL imaging biomarker assessment: contraindications to 3T MRI scanning, such as metal implants/non-compatible medical devices or medical conditions, including vagus nerve stimulator.
  • For subjects ELIGIBLE FOR EEG/ERP biomarker assessment: contraindications to EEG/ERP, such as uncooperative or destructive behaviors preventing lead placement or capture by ERP/VEP equipment. Under age 2 or over 11 at the time of enrollment.

Key Trial Info

Start Date :

May 1 2015

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

170 Patients enrolled

Trial Details

Trial ID

NCT02461446

Start Date

May 1 2015

End Date

December 1 2026

Last Update

October 26 2024

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

University of California at Los Angeles

Los Angeles, California, United States, 90095

2

Stanford University Medical Center

Stanford, California, United States, 94305

3

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

4

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations | DecenTrialz